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Abstract
Introduction Thyroid cancer (TC) incidence has been increasing in recent years. The aim of this study was to
investigate our institution-based estimates of operative volumes for TC over the last three decades.
Materials and methods This was a retrospective cohort study of patients undergoing thyroid surgery at our insti-
tution. Patient characteristics were reviewed in three subgroups: Group I (treated in 1981–1986), Group II (treated in
1987–2002), and Group III (treated in 2003–2012).
Results TC was diagnosed in 1578/17,526 (9.0 %) thyroid operations. Incidence of TC increased from 3.7 % in
Group I to 10.4 % in Group III (p\ 0.001). Incidence of papillary TC increased form 40.6 % in Group I to 81.3 % in
Group III (p\ 0.001). In the latter group, 23.5 % of all papillary TCs were diagnosed in patients with Hashimoto’s
disease. Meanwhile, incidence of anaplastic TC decreased from 16.2 % in Group I to 2.1 % in Group III patients
(p\ 0.001). pT1 tumors were diagnosed in 8.1 % Group I and 54.8 % Group III (p\ 0.001), whereas pT4 tumors
were identified in 40.5 % Group I, 2.4 % Group II, and 0.84 % Group III subjects (p\ 0.001). pT3 tumors were
found in 51.6 % Group I, whereas multifocal papillary TCs were found in 15.7 % Group III patients, the latter with a
higher prevalence of pN1 stage (p\ 0.001).
Conclusions The following trends in surgical volume for TC were identified throughout the study period: a fivefold
increase of thyroid operations for TC, a threefold increase in incidence of papillary TC, and an eightfold decrease in
incidence of anaplastic TC. It is of interest that a significant increase in incidence of multifocal papillary TC in young
female patients with Hashimoto’s disease was found over time.
Introduction
From the epidemiological viewpoint, thyroid cancer (TC)
occupies a distant place on the list of the most common
cancers, accounting for only 1 % of all malignancies, but at
the same time, it is the most common malignancy (up to
90 %) of the endocrine system and one of infrequent
cancers that are more prevalent in female than in male
patients. In recent years, the present authors have been
observing a clear increase of TC incidence, and its occur-
rence is associated with both an excess (papillary thyroid
cancer—PTC) and deficit (follicular thyroid cancer—FTC)
of dietary iodine. According to the International Agency
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for Research on Cancer (IARC), the TC incidence rate
worldwide falls within a wide range; regions with the
highest TC rate include the Pacific Islands (Hawaii),
Central America, Japan, East Asia (Korea, Hong Kong) as
well as Kuwait and Iceland [1–3]. Compared to other
countries, Poland represents rather low incidence rates,
nevertheless, according to the National Cancer Register
(NCR), the total number of malignant thyroid cases in the
Polish population has increased 4 times in females and 3
times in males within the past decades. The above ten-
dencies have been maintained for the past 20 years, indi-
cating that in the Polish society, no such significant
increase in the incidence rate has been noted in any other
location in the body. At present, it is difficult to say whe-
ther this phenomenon results from an absolute increase in
morbidity associated with changes in lifestyle, progressive
development of the industry and environmental effects,
e.g., ionizing radiation (the nuclear catastrophe in Cher-
nobyl), or else from an increase in detectability rates fol-
lowing the availability and improvement of diagnostic
techniques (USG ? FNAB). The problem is highly
important from both the medical and socio-economic
viewpoint. On the one hand, a long period of development
of highly differentiated thyroid cancer, which is the most
common and usually associated with a good prognosis,
poses a problem in studies on the epidemiology of this
tumor. On the other hand, in spite of improvement of the
afore-mentioned diagnostic methods, a high number of
cases of thyroid cancer (more than 30 %) are diagnosed
only in postoperative histopathology, what necessitates a
reoperation in the patient and is associated with increased
costs of treatment [4–8].
Clinical material originating from a uniform ethnic area
combined with experiences of a center that for many years
has been involved in surgical treatment of thyroid diseases
have made the authors inclined to perform a comparative
analysis of the incidence rates, stages, as well as changes
and tendencies in clinical presentation of patients operated
on due to thyroid cancer in the years 1981–2012.
Materials and methods
In the period between January 1981 and December 2012,
17,526 patients were operated on for various thyroid dis-
eases in the clinical center represented by the authors. Of
this number, 1578 surgical patients with diagnosed thyroid
cancer were selected and subsequently subdivided into
three groups, depending on the period when operated on.
Group I included patients treated in the years 1981–1986
(Group I n = 37), Group II in the period 1987–2002, i.e., at
various time intervals after the nuclear catastrophe in
Chernobyl (Group II n = 590), while the third group
consisted of subjects treated surgically in the years
2003–2012 (Group III, n = 951). All the patients were
classified in keeping with the most recent version of thy-
roid cancer classification TNM according to UICC (ed.VII,
2010) [9] by means of the analysis of data provided in
histological records collected in the Institutional Register
of Thyroid Surgery, the classification itself being based on
the above presented premises. In the analyzed material of
patients treated in the last decade (Group III), establishing
the final diagnosis was assisted by the use of immunohis-
tochemistry techniques in 158 (16.6 %) patients.
The collected clinical data were entered into spread-
sheets and served as the basis for the statistical analysis of
the results. The analysis assumed a 5 and 10-year follow-
up.
While analyzing the extent of the primary surgical
procedure in the presented groups, a simple division was
adopted into total and incomplete (partial resection,
subtotal resection, Dunhill procedure, lobectomy with
isthmectomy) thyroidectomy. In the analyzed period, all
the procedures were performed by an experienced surgical
team. The presence of cancer cells in the final histology
was an indication for a reoperation and resection of the
remaining thyroid tissue [10–14].
All the patients qualified for surgical treatment had
current results of TSH, fT4, and fT3 determinations, neck
ultrasound, chest X-ray. FNAB as a diagnostic method was
not routinely employed in the Group I and in some of Group
II patients, hence, it was not included in the presented
analysis. On the first postoperative day, all the patients were
subjected to indirect laryngoscopy in order to assess vocal
cord function, defining paresis as the number of nerves at
risk of injury. No restoration of normal mobility of vocal
cords after 12 months was defined as permanent paresis.
Each time, serum calcium levels were also determined
(reference level: 2.15–2.55 mmol/L) after 24 h, assuming
the diagnosis of hypocalcemia at the total calcium level
below 2.0 mmol/L. Adjuvant treatment, based on the rec-
ommendations of the Polish Neuroendocrine Tumor Net-
work Group (Polish Guidelines 2010), with radioactive
iodine, introduced in 1991, complemented the surgical
therapy and was a significant turning point in the strategy of
managing differentiated thyroid cancers. All the patients
after surgical treatment required L-tyrosine supplementa-
tion, the doses ensuring suppression for the following TSH
values: 0.1–0.3 mU/L in the low-risk group, and below
0.1 mU/L in the high-risk group. In addition to postopera-
tive determinations of thyroid-stimulating hormone (TSH),
the postoperative follow-up also included the levels of
thyroglobulin (TG) and anti-TG antibodies, ultrasonogra-
phy of the neck and scintiscan of the body.
The investigated groups of patients were compared with
respect to age, type, and clinical stage of carcinoma
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according to pTNM. The assessment of the changeability
of the investigated properties was presented as arithmetic
means and standard deviations (SD). In the statistical
analysis, variables with normal distribution were compared
using the Student’s t test, while for the remaining variables,
the v2 test was employed and in case of small sample
sizes—the Fisher’s exact test.
All the data were collected prospectively and stored in a
computer-based institutional register of thyroid surgery,
and analyzed retrospectively by a statistician. Statistical
analyses were performed with Statistica 10 for Windows
(StatSoft, Krakow, Poland).
Results
The analysis included 1578 (9.0 %) patients (TC) out of the
total number of subjects operated on for various thyroid
diseases; primary thyroid cancer was diagnosed in 1548
(98.1 %) patients. Thirty patients (1.9 %) with other types
of cancer metastasizing to the thyroid gland were excluded
from the analysis. While comparing the investigated
groups, the authors noted that initially, incomplete thy-
roidectomies predominated as the method of treating thy-
roid diseases, gradually giving way to total resection of
both thyroid lobes and central compartment lymph nodes
(according to the American Thyroid Association classifi-
cation), in keeping with the Polish Recommendations
modified since 2000. The number of patients followed-up
for 5 years was (1327) 84.1 %, while the 10-year follow-up
included (368) 23.3 % surgical patients.
Over the more than 30 years, a significant increase in
the number of surgical procedures performed in thyroid
tumors was seen, amounting respectively to 37 (3.7 %)
in Group I, 590 (7.9 %) in Group II and 951 (10.4 %) in
Group III. The values were statistically significant
(p\ 0.001) and illustrated a strong (fivefold) increase in
the number of surgical procedures performed due to
thyroid cancer. All the analyzed groups showed varied
ratios of male-to-female patients (Group I = 6:31; Group
II = 75:515; Group III = 110:841) however, the differ-
ences were statistically non-significant. The mean age of
the investigated patients was similar (Group
I = 52.0 ± 15.96; Group II = 52.3 ± 15.42; Group
III = 52.43 ± 12.7), with a clearly visible tendency
towards an increasing risk of thyroid cancer in the
population of females in the lower age range, below
45 years of life (\45 years.: Group I: 8 = 21.60 % vs.
Group II: 254 = 43.1 % and Group III: 407 = 42.8 %;
C45 years.: Group I: 29 = 78.4 % vs. Group II:
336 = 56.9 % and Group III: 544 = 57.2 %). In all the
groups, papillary thyroid cancer predominated (Group
I = 15 (40.6 %); Group II = 405 (68.6 %); Group
III = 773 (81.9 %). The values were statistically signif-
icant (p\ 0.001). In the last decade, a significant per-
centage of papillary thyroid cancer (PTC with HT:
130 = 23.5 %) was concomitant with autoimmune thy-
roid diseases. The analyzed groups significantly differed
with respect to the percentage of anaplastic thyroid
cancer—6 (16.2 %) in Group I, 46 (7.8 %) in Group II,
and 20 (2.1 %) in Group III (p\ 0.001), denoting a
considerable (eightfold) decrease of the number in the
analyzed material. A similar decreasing trend was
observed in the percentage of follicular thyroid cancer,
which was consistently reduced from 9 cases (24.3 %) in
Group I to 91 (9.6 %) in Group III [(Group I = 9
(24.3 %); Group II = 89 (15.1 %); Group III = 91
(9.6 %)] (p = 0.01). In the analyzed groups, following
the primary procedure, the operation was evaluated as
macroscopically residual disease (R2) in 12 (34.4 %)
Group I patients, 57 (9.7 %) Group II subjects, and in 4
(0.42 %) patients in Group III (p\ 0.001) (Table 1).
All the compared groups of patients also differed with
respect to the clinical stage of the tumor at surgery.
Stage pT1 was observed in 3 (8.1 %) Group I patients,
22 (37.6 %) Group II subjects, and 521 (54.8 %) Group
III individuals (p\ 0.001), while pT4 was seen,
respectively in 15 (40.5 %) Group I patients, 14 (2.4 %)
in Group II, and 8 (0.84 %) in Group III (p\ 0.001). No
pT2 tumors were seen in Group I, while an increase of
such diagnoses was noted 20 years previously in Group
II—267 (45.3 %), and the rate observed in Group III was
constant and unchangeable within the last decade—264
(27.8 %). pT3 stage tumors also predominated in Group
I—19 (51.6 %) patients; while multifocal tumors with a
higher tendency to metastasizing to the lymph nodes
were more often seen in Group III—149 (15.7 %)
patients. A statistically significant difference was noted
in case of lymph node metastases, which predominated
in Group III (Group I = 5 (13.5 %); Group II = 108
(18.3 %); Group III = 323 (34.0 %) (p\ 0.001) contrary
to M1, which was significantly higher in Group I than in
Group III (p\ 0.01). The mean size of the largest single
tumor focus differed in the analyzed material; tumors
with larger diameter predominated in Group I (Group
I = 40.17 ± 24.9 mm; Group II = 19.9 ± 27.3 mm;
Group III = 9.5 ± 15.96 mm) (p = 0.01) (Tables 1, 2).
The analyzed groups significantly differed with respect
to complications rate; the authors noted a decreased num-
ber of vocal cord paresis [(Group I = 11 (14.8 %); Group
II = 54 (4.6 %); Group III = 71 (3.70 %)] with a simul-
taneous increase in the percentage of transient
hypoparathyroidism [Group I = 5 (13.5 %); Group
II = 143 (24.2 %); Group III = 264 (27.8 %)] (Table 3).
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Discussion
Thyroid cancer is not found among common tumors. Its
incidence is rather low; nevertheless, according to the
available data, in the last two decades, the overall
morbidity in the Polish population has increased more than
fourfold in women and threefold in men. The above ten-
dencies have allowed for formulating a conclusion that
there is a significant increase in thyroid cancer incidence
that is not observed in tumors situated elsewhere [5, 6].
Table 1 Clinical and histopathological factors characteristics of patients with thyroid cancer operated on the years 1981–2012
Group I [n (%)] [37
(3.7)]
Group II [n (%)] [590
(7.9)]
Group III [n (%)] [951
(10.4)]
p
Sex ratio (M:F) 6:31 75:515 110:841 NS
Age (years) NS
Mean (SD) 52.0 ± 15.96 52.3 ± 15.42 52.4 ± 12.71
\45[n (%)] 8 (21.6) 254 (43.1) 407 (42.8)
C45 [n (%)] 29 (78.4) 336 (56.9) 544 (57.2)
Extension of resection of thyroid gland R2 [n (%)] 12 (34.4 %) 57 (9.7) 4 (0.42) \0.001
Histopatology [n (%)]
Papillary TC 15 (40.6) 405 (68.6) 773 (81.3)* \0.001
Follicular TC 9 (24.3) 89 (15.1) 91 (9.6) \0.001
Hurthl’e cell TC 0 16 (2.7) 14 (1.4) NS
Medullary TC 1 (2.7) 16 (2.7) 21 (2.2) NS
Anaplastic 6 (16.2) 46 (7.8) 20 (2.1) \0.001
Metastases to thyroid 5 (13.5) 12 (2.0) 13 (1.4) 0.035
Another TC
Lymphoma, Schwannoma, Sarcoma,
Planoepithelial TC
1 (2.7) 6 (2.0) 19 (2.0) NS
Diameter of the largest foci in mm, mean ± SD 40.17 ± 24.9 19.9 ± 27.3 9.5 ± 15.96 \0.001
* 23.5 % PTC with Hashimoto thyroiditis (PTC with HT)
(p\ 0.001); NS non-significant
Table 2 TNM factors characteristics of patients with thyroid cancer operated on the years 1981–2012
Group I [n (%)] [37 (3.7)] Group II [n (%)] [590 (7.9)] Group III [n (%)] [951 (10.4)] p
p\ 0.001
pT category [n (%)]
pT1 3 (8.1) 222 (37.6) 521 (54.8) <0.001
pT2 0 (0) 267 (45.3) 264 (27.8) \0.001
pT3 19 (51.6) 87 (14.7) 158 (16.6) \0.001
pT4 a 15 (40.5) 14 (2.4) 8 (0.8) <0.001
Multifocal lesions [n (%)] 1 (2.7) 156 (25.4) 149 (15.7) \0.001
Capsular infiltration 34 (91.9) 137 (23.3) 87 (9.1) \0.010
pN1 5 (13.5) 108 (18.3) 323 (34.0) <0.001
M 3 (8.1) 23 (3.9) 11 (1.2) \0.001
TNM stage
I 3 (8.1) 247 (41.9) 570 (59.9) \0.001
II 0 (0) 152 (25.8) 91 (9.6) \0.001
III 17 (46.0) 176 (29.8) 281 (29.5) NS
IVa 13 (35.1) 15 (2.5) 9 (1.0) \0.001
IVb 4 (10.8) 0 (0) 0 (0) \0.001
(p\ 0.001); NS non-significant
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The afore-mentioned trend is also noticeable in the
majority of countries worldwide, including countries of
Western Europe (excluding Norway and Sweden) and in
North America. In the United States, during the last
10 years, an approximately threefold increase of thyroid
cancer was observed. [15–19].
In the present material, the percentage of cancers among
patients operated on due to various thyroid diseases also
profoundly increased, from 3.7 % in the years 1982–1986
to 10.4 % by the end of 2012. Nevertheless, a fivefold
increase in the total number of operations for goiter should
be also emphasized. The explanation of this trend continues
to provoke acute controversies. Do we indeed face an
increase in the incidence rate of thyroid cancer? The
availability of various diagnostic imaging studies (USG,
USG Doppler, computed tomography, magnetic resonance
MRI, or PET-CT), and laboratory tests has affected the
detectability rate of all types of cancers, also including
thyroid cancer. Thyroid ultrasonography performed inci-
dentally while studying blood flow in the cervical vessels
may be here a good example of detecting small, palpably
non-diagnostic lesions of the thyroid gland. On the one
hand, further diagnostic management follows, which
includes fine-needle aspiration biopsy and may be at the
same time an indication for a surgical procedure, but on the
other, it increases the cost of the procedures. From the
medical point of view, detecting a lesion that is in its
preclinical stage is absolutely justified and even in view of
the slow dynamics of lesion development in differentiated
thyroid cancers, considering prolonged mean lifespan
noted in the majority of societies, this is a sound man-
agement strategy. A strong argument in favor of this fact is
limiting the number of difficult reoperations and by the
same token, possible complications, and the continuously
high number of thyroid cancers that are detected
incidentally, although the number and accuracy of FNAB
procedures have considerably improved [10, 20–23].
But is it only improved detectability rate that builds the
foundations for the increased number of thyroid cancers? If
it were so, then with an increasing number of detected
small foci of thyroid cancer, there should be noted a con-
sistent decrease in the number of high-stage forms and the
total number of tumors. Is it really so? Over the past few
years, in the present material, a trend is invariably seen
towards a decrease in the number of high-stage forms with
infiltration of the capsule and the surrounding structures
(pT4: 15 (40.5 %) in Group I, 14 (2.4 %) in Group II, and 8
(0.84 %) in Group III (p\ 0.001)) in favor of small-sized
primary tumors (pT1: 3 (8.1 %) in Group I, 22 (37.6 %) in
Group II and 521 (54.8 %) in Group III (p\ 0.001). Also
the mean size of the largest primary foci decreased,
respectively, from 40.17 ± 24.9 mm in Group I to\1 cm
in Group III (Group III = 9.5 ± 15.96 mm) (p = 0.01);
nevertheless, the tendency towards an increase of the
absolute number of thyroid cancers has been maintained.
While analyzing the material, the authors have noted that
the group of thyroid cancers with a primary focus greater
than 2 cm but smaller than 4 cm has been maintained on
the same, fairly unchangeable level. If we thus assume that
the availability and development of modern diagnostic
methods facilitates detection of small lesions, then clini-
cally detectable by palpation tumors constitute an impor-
tant group that plays a decisive role in the absolute increase
of the number of thyroid cancers. Similar observations
have been also made by authors from other countries [24–
26].
All the above publications address the analysis of thy-
roid cancer histiotypes and clearly indicate the prevailing
character of papillary carcinoma. A similar situation was
noted in the present clinical material, which clearly pointed
Table 3 Complications after thyroidectomy in patients with TC involved in this study
Group I [n (%)] [37
(3.7)]
Group II [n (%)] [590
(7.9)]
Group III [n (%)] [951
(10.4)]
p
Parathyroid found in pathological report,
[n (%)]
No data 31 (5.3) 68 (7.2) 0.139
Hypoparathyroidism, [n (%)] Total 5 (13.5) 143 (24.2) 264 (27.8) 0.065
Transient (\12 month) 4 (10.1) 135 (22.9) 248 (26.1) 0.053
Permanent ([12 month) 1 (2.7) 8 (1.3) 16 (1.7) 0.758
Unilateral RLN injury, [n.(%)]
Total 11 (14.8) 54 (4.6) 71 (3.7) \0.001
Transient (\12 month) 8 (10.8) 40 (3.4) 52 (2.7) \0.001
Permanent ([12 month) 3 (4.0) 14 (1.2) 19 (1.0) 0.051
RLN recurrent laryngeal nerve
 RLN injury was calculated for nerves at risk and not for patients (there were 74 nerves at risk in Group I; 1180 in Group II; 1902 in Group III)
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to an increase of the number of this type of highly differ-
entiated thyroid cancers from 40.6 % in the first analyzed
group to more than 80 % in Group III (Group I = 15
(40.6 %); Group II = 405 (68.6 %); Group III = 773
(81.9 %). The difference was statistically significant
(p\ 0.001). In turn, follicular carcinoma predominated in
Group I (24.3 %), to become stabilized over subsequent
years at the level of 10–15 % of all thyroid cancers (Group
II = 89 (15.1 %); Group III = 91 (9.6 %)). (p = 0.01).
The data are similar to findings presented by other authors
[27, 28].
Based on the analysis of the present material, one may
state that the above observations may result from the fol-
lowing causes: firstly—from the effect of iodine prophy-
laxis carried out in Poland, which significantly affected the
increase in the percentage of papillary carcinoma, with a
decrease in the number of new cases of follicular carci-
noma, secondly—from the improved detectability in
biopsy materials, and thirdly—as the consequence of re-
analysis of histological diagnoses based on immunohisto-
chemistry, what allows for differentiating between the
follicular variant of papillary cancer and follicular carci-
noma by means of e.g., cytokeratin 19 determinations [29].
Attention should be also directed to the clearly visible
increase in concomitant occurrence of papillary thyroid
carcinoma and thyroid autoimmune diseases, predomi-
nantly Hashimoto’s thyroiditis [30–33].
While analyzing other subtypes of thyroid cancer in the
present material, the authors noted a statistically significant
decrease in the percentage of anaplastic cancer from 16.2 %
in Group I to 2.1 % in Group III (6 (16.2 %) in Group I, 46
(7.8 %) in Group II, and 20 (2.1 %) in Group III
(p\ 0.001)). Based on the analysis of our material and the
review of literature, development and availability of mod-
ern immunohistochemical methods have favorably affected
the higher detectability rate of lymphomas and mixed forms
of anaplastic thyroid cancer. An important factor in the
etiopathogenesis of this cancer subtype is a long-term his-
tory of nodular goiter. Undoubtedly, the profound decrease
in the number of anaplastic cancer cases results from a
higher availability of diagnostics tests and a decidedly
higher number of performed surgical procedures [10].
Another statistically significant difference observed in the
analyzed groups was lymph node involvement. In the pre-
sent material, the authors noted a consistent increase of the
number of involved lymph nodes from 13.5 % in Group I to
34.0 % in Group III [(Group I = 5 (13.5 %); Group
II = 108 (18.3 %); Group III = 323 (34.0 %) (p\ 0.001)].
The above tendencies were also seen in other countries, e.g.,
in more than one-half of the investigated Belarus children
after the Chernobyl catastrophe and in the studied Italian and
French populations [34]. In the present analysis, the higher
percentage of the involved lymph nodes in the investigated
Group III was undoubtedly affected by the strategy of sur-
gical management consisting in total extracapsular thy-
roidectomy along with resection of the central compartment
lymph nodes in all cases suspected of thyroid cancer based
on the material obtained by fine-needle aspiration biopsy.
Although preventive lymphadenectomy in papillary thyroid
cancer continues to be highly controversial in view of a
higher probability of complications manifested as transient
hypoparathyroidism, which—according to data from the
literature—is clearly on the rise in this group of patients,
such a strategy is also supported by numerous solid argu-
ments. Prophylactic lymphadenectomy of compartment VI
cervical lymph nodes often allows for correct determination
of tumor stage VI and detection of metastases in preclinical
stage, affects formulation of indications for further adjuvant
therapy and contributes to decreasing the number of reop-
erations, thus decreasing the risk of permanent damage to the
recurrent laryngeal nerves and hypoparathyroidism. Based
on the analysis of the present material, one may state that an
increase in the number of cases of transient hypoparathy-
roidism [Group I = 5 (13.5 %); Group II = 143 (24.2 %);
Group III = 264 (27.8 %)] was a consequence of extending
the scope of the procedure to include lymphadenectomy of
the central compartment lymph nodes, but it also affected the
reclassification of tumor stage and shifting patients from
Group II to Group III [32, 35, 36].
In summary, it may be stated that despite the fact that
from the standpoint of epidemiology, thyroid cancers
occupy a distant place accounting for a small percentage of
all malignancies, nevertheless, within the past 30 years, a
dynamic increase in the incidence of this type of cancer has
been observed. Slow dynamics of lesion development and
favorable prognoses in the group of highly differentiated
thyroid cancers maintain the mortality rate on a continu-
ously unchanged level. Nevertheless, on the one hand, the
increase in its incidence in younger women should be borne
in mind, and on the other—a prolonged mean lifespan in
developed countries; these are important factors in planning
the strategy of surgical treatment. In the opinion of the
present authors, the above epidemiological considerations
and constant improvement of diagnostic methods have
become an important element that plays a decisive role in
selecting therapeutic methods based on specialized centers.
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